01498 Relative Valuation
01498's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 01498 is overvalued; if below, it's undervalued.
Historical Valuation
PURAPHARM (01498) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 6.98. The fair price of PURAPHARM (01498) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.34
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
PURAPHARM. (01498) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 4.47. The thresholds are as follows: Strongly Undervalued below -3.01, Undervalued between -3.01 and 0.73, Fairly Valued between 8.21 and 0.73, Overvalued between 8.21 and 11.95, and Strongly Overvalued above 11.95. The current Forward EV/EBITDA of 0.00 falls within the Undervalued range.
6.56
EV/EBIT
PURAPHARM. (01498) has a current EV/EBIT of 6.56. The 5-year average EV/EBIT is 13.63. The thresholds are as follows: Strongly Undervalued below 3.28, Undervalued between 3.28 and 8.46, Fairly Valued between 18.81 and 8.46, Overvalued between 18.81 and 23.99, and Strongly Overvalued above 23.99. The current Forward EV/EBIT of 6.56 falls within the Undervalued range.
0.00
PS
PURAPHARM. (01498) has a current PS of 0.00. The 5-year average PS is 0.27. The thresholds are as follows: Strongly Undervalued below -0.20, Undervalued between -0.20 and 0.04, Fairly Valued between 0.50 and 0.04, Overvalued between 0.50 and 0.73, and Strongly Overvalued above 0.73. The current Forward PS of 0.00 falls within the Undervalued range.
0.00
P/OCF
PURAPHARM. (01498) has a current P/OCF of 0.00. The 5-year average P/OCF is 2.94. The thresholds are as follows: Strongly Undervalued below -2.08, Undervalued between -2.08 and 0.43, Fairly Valued between 5.45 and 0.43, Overvalued between 5.45 and 7.96, and Strongly Overvalued above 7.96. The current Forward P/OCF of 0.00 falls within the Undervalued range.
2.04
P/FCF
PURAPHARM. (01498) has a current P/FCF of 2.04. The 5-year average P/FCF is 4.48. The thresholds are as follows: Strongly Undervalued below 0.65, Undervalued between 0.65 and 2.56, Fairly Valued between 6.40 and 2.56, Overvalued between 6.40 and 8.32, and Strongly Overvalued above 8.32. The current Forward P/FCF of 2.04 falls within the Undervalued range.
PURAPHARM (01498) has a current Price-to-Book (P/B) ratio of 1.36. Compared to its 3-year average P/B ratio of 1.99 , the current P/B ratio is approximately -31.56% higher. Relative to its 5-year average P/B ratio of 1.60, the current P/B ratio is about -14.84% higher. PURAPHARM (01498) has a Forward Free Cash Flow (FCF) yield of approximately 42.27%. Compared to its 3-year average FCF yield of 27.24%, the current FCF yield is approximately 55.18% lower. Relative to its 5-year average FCF yield of 18.38% , the current FCF yield is about 129.95% lower.
1.36
P/B
Median3y
1.99
Median5y
1.60
42.27
FCF Yield
Median3y
27.24
Median5y
18.38
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 01498 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01498 in the past 1 year is driven by Unknown.
People Also Watch
WMT
Walmart Inc
113.07USD
0.31%
AAPL
Apple Inc
259.04USD
-0.50%
AVGO
Broadcom Inc
332.48USD
-3.21%
XOM
Exxon Mobil Corp
122.91USD
3.73%
AMZN
Amazon.com Inc
246.26USD
1.95%
TSLA
Tesla Inc
435.8USD
1.02%
NVDA
NVIDIA Corp
185.04USD
-2.15%
ORCL
Oracle Corp
189.65USD
-1.65%
MSFT
Microsoft Corp
478.11USD
-1.11%
META
Meta Platforms Inc
646.06USD
-0.41%
Frequently Asked Questions
Is PURAPHARM (01498) currently overvalued or undervalued?
PURAPHARM (01498) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 6.98. The fair price of PURAPHARM (01498) is between to according to relative valuation methord.
What is PURAPHARM (01498) fair value?
01498's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of PURAPHARM (01498) is between to according to relative valuation methord.
How does 01498's valuation metrics compare to the industry average?
The average P/S ratio for 01498's competitors is , providing a benchmark for relative valuation. PURAPHARM Corp (01498) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for PURAPHARM (01498) as of Jan 08 2026?
As of Jan 08 2026, PURAPHARM (01498) has a P/B ratio of 1.36. This indicates that the market values 01498 at 1.36 times its book value.
What is the current FCF Yield for PURAPHARM (01498) as of Jan 08 2026?
As of Jan 08 2026, PURAPHARM (01498) has a FCF Yield of 42.27%. This means that for every dollar of PURAPHARM’s market capitalization, the company generates 42.27 cents in free cash flow.
What is the current Forward P/E ratio for PURAPHARM (01498) as of Jan 08 2026?
As of Jan 08 2026, PURAPHARM (01498) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of PURAPHARM’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for PURAPHARM (01498) as of Jan 08 2026?
As of Jan 08 2026, PURAPHARM (01498) has a Forward P/S ratio of 0.00. This means the market is valuing 01498 at $0.00 for every dollar of expected revenue over the next 12 months.